Finally, new IL-1-inhibiting agents, including canakinumab, gevokizumab, and rilonacept, which are not associated with the discomfort of daily injection, already showed some efficacy in RA and T2D [6,36,46,48–50]. This evidence concerns the gene IL1B and type 2 diabetes mellitus.